Redmile Group, LLC Xenon Pharmaceuticals Inc. Transaction History

Redmile Group, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$34.84 - $43.54 $7.15 Million - $8.94 Million	-205,356 Reduced 15.49%	1,120,476 $43.1 Million
Q1 2023 May 15, 2023	SELL	$33.46 - $40.35 $34.6 Million - $41.7 Million	-1,034,582 Reduced 43.83%	1,325,832 $47.5 Million
Q4 2022 Feb 14, 2023	SELL	$33.06 - $39.43 $337,212 - $402,186	-10,200 Reduced 0.43%	2,360,414 $93.1 Million
Q3 2022 Nov 14, 2022	BUY	$30.79 - $39.82 $22.5 Million - $29.1 Million	731,270 Added 44.61%	2,370,614 $85.6 Million
Q2 2022 Aug 15, 2022	BUY	$25.44 - $35.16 $41.7 Million - $57.6 Million	1,639,344 New	1,639,344 $49.9 Million

212

70.2M

88.3K

28.8K

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.39B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.